Globus Medical Inc. Class A Common Stock vs Materials Select Sector SPDR Fund — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Materials Select Sector SPDR Fund trades at $50 (market cap $7.85B). The key difference: Globus Medical Inc. Class A Common Stock is the larger of the two by market cap, and Materials Select Sector SPDR Fund is trading nearer its 52-week high, Globus Medical Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Materials Select Sector SPDR Fund for 71 Days on average.
| GMED | XLB | |
|---|---|---|
Market Cap | $10.25B | $7.85B |
Volume | 1,108,124 | 7,897,808 |
Sector | Health | — |
52-Week High | $96.82 | $53.67 |
52-Week Low | $58.33 | $42.23 |
Typical Hold Time | 0 Days | 71 Days |
Enterprise Value | $9.76B | — |
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
XLB trades at $49.72 with a modest 0.57% daily gain, though technical indicators signal bearish momentum with moving averages and ADX pointing lower. The materials ETF faces headwinds from sector concentration risks, with chemicals comprising 49% of assets. Recent analysis suggests much of the cyclical recovery appears priced in, limiting near-term upside potential despite infrastructure and manufacturing tailwinds.
Outlook remains cautious as technical weakness combines with valuation concerns. The ETF offers efficient exposure to materials but faces competition from AI-focused sectors. Key risks include sector concentration and cyclical sensitivity, while potential catalysts include infrastructure spending and supply chain diversification efforts.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →